XORTX Therapeutics Inc.
XRTX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.71% | -28.10% | -42.97% | -4.87% | -18.58% |
| Depreciation & Amortization | 11.49% | 13.51% | -16.36% | -19.00% | 6.97% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.41% | -21.06% | -26.19% | 27.68% | -32.68% |
| Operating Income | -27.41% | 21.06% | 26.19% | -27.68% | 32.68% |
| Income Before Tax | -582.04% | -10.65% | -521.93% | 76.86% | -95.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -582.04% | -10.65% | -521.93% | 76.86% | -95.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -582.04% | -10.65% | -521.93% | 76.86% | -95.46% |
| EBIT | -27.41% | 21.06% | 26.19% | -27.68% | 32.68% |
| EBITDA | -28.25% | 18.82% | 24.44% | -33.25% | 33.14% |
| EPS Basic | -341.18% | 33.88% | -423.38% | 84.95% | -97.23% |
| Normalized Basic EPS | -340.17% | 33.86% | -423.50% | 84.96% | -97.23% |
| EPS Diluted | -341.82% | 33.88% | -424.23% | 84.71% | -97.24% |
| Normalized Diluted EPS | -340.17% | 33.86% | -423.50% | 84.96% | -97.23% |
| Average Basic Shares Outstanding | 99.77% | 67.26% | 30.47% | 53.83% | 63.88% |
| Average Diluted Shares Outstanding | 99.77% | 67.26% | 30.47% | 53.83% | 63.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |